Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
26 hedge funds and large institutions have $1.95M invested in Carisma Therapeutics in 2017 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 6 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
0.23% less ownership
Funds ownership: 0.48% → 0.25% (-0.23%)
4% less funds holding
Funds holding: 27 → 26 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
63% less capital invested
Capital invested by funds: $5.26M → $1.95M (-$3.31M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $8K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$186K |
| 2 |
SIM
Spark Investment Management
New York
|
+$158K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
+$82.8K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$51K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$40.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
-$2.91M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$207K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$65K |
| 4 |
EGA
Eagle Global Advisors
Houston,
Texas
|
-$58K |
| 5 |
Goldman Sachs
New York
|
-$35K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GCP
26
GSA Capital Partners
London,
United Kingdom
| – | -$207K | -4,695 | Closed |
|
|
27
Citadel Advisors
Miami,
Florida
| – | -$65K | -1,480 | Closed |
|
|
EGA
28
Eagle Global Advisors
Houston,
Texas
| – | -$58K | -1,327 | Closed |
|
|
29
Goldman Sachs
New York
| – | -$35K | -791 | Closed |
|
|
FPF
30
FNY Partners Fund
New York
| – | -$11K | -250 | Closed |
|
|
CG
31
Cutler Group
San Francisco,
California
| – | -$1.1K | -33 | -59% |
|
32
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$834 | -25 | -71% |
|
CARM Hedge Fund Activity: Q2 2017 in Review
26 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q2 2017, worth a combined $1.95M — down 63% from $5.26M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CARM and 5 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 7 added.
The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $186K. The largest seller was Flagship Pioneering, exiting entirely with an estimated $2.91M sold.
- 26 institutional investors held Carisma Therapeutics (CARM) as of Q2 2017, down from 27 in Q1 2017.
- Funds reported $1.95M of Carisma Therapeutics stock for Q2 2017, down 63% quarter-over-quarter.
- 5 funds opened new Carisma Therapeutics positions in Q2 2017 and 6 closed out, a net change of -1 holder.
- The largest Carisma Therapeutics buyer in Q2 2017 was Virtu KCG Holdings, an estimated $186K added.
- The largest Carisma Therapeutics seller in Q2 2017 was Flagship Pioneering, an estimated $2.91M sold.
Based on aggregated 13F filings for Q2 2017.